Childhood asthma
Conditions
Interventions
None listed
Sponsors
Lawson Health Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Children and adolescents 6 to 18 years of age with physician-diagnosed stable, persistent asthma on a daily dose of one of the 4 studied ICS, administered via MDI with holding chamber (AeroChamber with mouth piece), or in case of budesonide +/- formoterol via DPI. - No change in their prescribed ICS treatment dose for at least 1 month prior to enrollment. - Ability to correctly take the medication as assessed by a member of the research team. - Compliant with medication (assessed by history given by child and caretaker)
Exclusion criteria
Exclusion criteria: - Individuals who do not speak and understand English - ICS used with other than the defined devices (see inclusion criteria) - Inability to correctly take the medication with the required device - Poor adherence to studied ICS (more than 2 missed doses per week)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum concentration of beclomethasone 17-monopropionate, budesonide, fluticasone propionate, or des-ciclesonid at the respective expected Tmax following inhalation of the patient's regular prescribed dose. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Percentage of drug serum concentration detected at Tmax after inhalation, of total inhaled dose. 2) Fold-increase from baseline to Tmax after drug inhalation. 3) Differences between the investigated ICS products with regard to their baseline and peak serum concentrations. | — |
Countries
North America
Contacts
Public ContactMelinda Pihokker
Children's Hospital, London Health Sciences Centre Paediatrics
Outcome results
None listed